|
|
News Breaks | | | | March 7, 2013 | | 06:09 EDT |  | INO | Inovio Pharma raises $15.1M in common stock and warrants
Inovio announced that it has priced an underwritten offering of 27,377,266 shares of its common stock and warrants to purchase up to 13,688,633 shares of common stock at a combined price to the public of $0.55 per share and related warrant for gross proceeds of $15.1M. The warrants are exercisable at an exercise price of $.7936 per share and will expire, unless exercised, on the date that is 180 days after the fifth anniversary of the date of issuance. Cowen and Company, LLC is acting as sole book-running manager for the offering. Brean Capital, LLC is acting as co-lead manager for the offering. Maxim Group LLC is acting as co-manager. | |
|
News For INO From The Last 14 Days Check below for free stories on INO the last two weeks. |
|
|
| May 14, 2013 | | 09:18 EDT |  | INO | Inovio announces positive results from preclinical study of SynCon DNA vaccine
Inovio announced that in a preclinical study of Inovio's SynCon DNA vaccine against Ebola and Marburg filoviruses, labeled "Category A" bioterrorism agents by the U.S. government, the vaccine induced strong and broad immune responses and demonstrated 100% protection against death following a challenge with multiple variants of the pathogen in two animal models. | |
|
|
|
|
|
|
